title: Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report.
abstract: OBJECTIVE
  Recent success in polychemotherapy (PCT) in adolescent female cancer patients has become a source of concern for specialists who also strive to preserve fertility. We studied whether gonadotropin-releasing hormone (GnRH) analogs could prevent the early onset of ovarian insufficiency postchemotherapy and protect fertility.
  
  
  METHODS
  The patients were divided into three groups: Control group 1 (Group A), premenarchal patients aged 3 to 7.5 years (n = 5), were not given GnRH analogs administered prior to PCT. Postmenarchal patients (Group B), aged 14.7 to 20 years (n = 12) with normal menstrual rhythm and ovulatory cycles, received treatment with GnRH analogs prior to PCT. Control group 2 (Group C), postmenarchal patients aged 15.9 to 20 years (n = 4), received PCT but no GnRH analog protection. All groups received the PCT regimens CAVPE, CVPP, ABVD, TAMO, ARA-C, and MTT. In group B, leuprolide acetate inhibition was obtained with a depot injection administered each month before and during treatment with PCT. To accelerate the timing of ovarian regression, a subcutaneous injection (0.2 mg) was administered simultaneously.
  
  
  RESULTS
  In Group A, patients had spontaneous menarche between the ages of 12 and 17.9 years, followed by normal menstruation and ovulatory cycles. Three patients became pregnant. After GnRH analog withdrawal, Group B patients continued with normal ovulatory cycles. Two patients became pregnant. Group C patients presented hypergonadotrophic hypoestrogenic amenorrhea.
  
  
  CONCLUSIONS
  GnRH analog treatment before and during PCT enhances ovarian function and preserves adolescent fertility. The results must be confirmed in a larger study.
authors.affiliation: Pediatric and Adolescent Gynecology Section, Hospital de Clinicas, Universidad de Buenos Aires, Argentina. pereyrapachecob@vianetworks.com.ar
authors.forename: B
authors.initials: B
authors.lastname: Pereyra Pacheco
authors.forename: J M
authors.initials: JM
authors.lastname: Méndez Ribas
authors.forename: G
authors.initials: G
authors.lastname: Milone
authors.forename: I
authors.initials: I
authors.lastname: Fernández
authors.forename: R
authors.initials: R
authors.lastname: Kvicala
authors.forename: T
authors.initials: T
authors.lastname: Mila
authors.forename: A
authors.initials: A
authors.lastname: Di Noto
authors.forename: O
authors.initials: O
authors.lastname: Contreras Ortiz
authors.forename: S
authors.initials: S
authors.lastname: Pavlovsky
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D005298:Fertility / Q000187:drug effects*; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007246:Infertility / Q000139:chemically induced / Q000517:prevention & control*; D016729:Leuprolide / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008597:Menstrual Cycle / Q000187:drug effects; D010053:Ovary / Q000187:drug effects* / Q000502:physiology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D011247:Pregnancy; D013945:Thymoma / Q000188:drug therapy
chemical_list: D005300:Fertility Agents, Female; D016729:Leuprolide